HealthEquity’s Q1 2027 earnings snapshot

HealthEquity (HQY) opened its Q1 2027 report with total revenue of US$354.6 million and basic EPS of US$0.82, supported by net income of US$69.4 million. Over the past six quarters, revenue has moved from US$311.8 million in Q4 2025 to US$354.6 million in Q1 2027, while quarterly basic EPS has ranged from US$0.30 to US$0.82, and trailing twelve month EPS has reached US$2.70 on revenue of about US$1.3 billion. With trailing net profit margins reported higher than last year, these results put profitability at the center of the story for investors reviewing the latest numbers.

See our full analysis for HealthEquity.

Next up is how these fresh results line up with the dominant market narratives around growth, quality, and risk, and where the numbers start to challenge those storylines.

TTM earnings up 89% and margins at 17.3%

• Over the last twelve months, net income was US$230.7 million on US$1.34b of revenue, which works out to a 17.3% net margin compared with 9.8% a year earlier.
• Analysts' bullish view leans heavily on this profitability shift, arguing that higher margins can support future growth. However, the consensus narrative also flags pressure points such as healthcare cost inflation and rising competition that could make it harder to maintain a 17.3% margin if operating costs or fee pressure pick up.

Q1 EPS sits within a much stronger earnings run-rate

• Q1 2027 basic EPS of US$0.82 compares with a trailing twelve month EPS of US$2.70, showing that the latest quarter fits into a period where earnings over the last year rose 89.4% compared with the prior year.
• Consensus narrative points to regulatory changes and digital tools as supports for earnings, and the recent EPS run-rate connects to that view. There is also a bearish angle in the same narrative that highlights interest rate dependency and a soft labor market, which could pressure HSA balances and account additions if conditions turn, making this high trailing growth rate harder to repeat.

On this kind of run-rate and margin profile, bulls argue there is more room for earnings to grow, while bears keep pointing back to macro and rate sensitivity as potential brakes on that story. 🐂 HealthEquity Bull Case

Valuation sits between industry and peers

• HealthEquity trades on a trailing P/E of 31.9x, which is above the broader US Healthcare industry at 23.2x but below the peer group average of 67.5x. The current share price of US$87.99 sits below both a DCF fair value of about US$166.05 and an analyst target level of US$114.56.
• Skeptics focus on the premium to the wider industry and on forecasts that show revenue and earnings growth rates of 7.3% and 14.8% a year trailing the broader US market at 11.8% and 17%. The bullish side of the consensus narrative leans on diversified fee streams and cost efficiencies to argue that the current P/E and the gap to the DCF fair value and analyst target could be justified if those trends hold.

Skeptics point to the valuation premium and slightly slower forecast growth as reasons for caution, even as others focus on the earnings record and internal value estimates when weighing the stock. 🐻 HealthEquity Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for HealthEquity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all this in mind, are you leaning bullish or cautious on HealthEquity, and how quickly will you check the details for yourself? To see what investors are optimistic about, review the 4 key rewards

See What Else Is Out There

HealthEquity’s premium P/E, slower forecast growth than the broader US market, and exposure to macro and rate sensitivity leave some investors looking for steadier options.

If you want ideas that lean more on stability and downside protection, especially when you are concerned about macro risks, check out 62 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.